Spherix Global Insights’ recent study of US hematologists reveals growing confidence in gene therapies like Casgevy and Lyfgenia for...

Scilex Holding Company (Nasdaq: SCLX) will present a post-hoc analysis of the C.L.E.A.R. trial at the 27th Annual Meeting...

4D Molecular Therapeutics (4DMT) has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its product 4D-150,...

Design Therapeutics announced positive Phase 1 trial data for DT-168, an eye drop formulated to treat Fuchs endothelial corneal...

Anavex Life Sciences Corp. has completed enrollment in its Phase 2 clinical trial (ANAVEX3-71-SZ-001) of ANAVEX®3-71 for schizophrenia treatment....

Bio-Path Holdings announced positive preclinical results for BP1001-A, a potential obesity and Type 2 diabetes treatment. The drug candidate...

Biosplice Therapeutics has initiated a Phase 2 clinical trial of its CLK/DYRK kinase inhibitor, cirtuvivint, in patients with advanced...

OBI Pharma, a clinical-stage oncology company, received FDA clearance for an Investigational New Drug (IND) application for OBI-902, a...

Nxera Pharma’s partner, Neurocrine Biosciences, has launched a Phase 3 trial for NBI-1117568, an oral M4 selective receptor agonist,...

A new study in Cancer Diagnosis & Prognosis shows that Castle Biosciences’ DecisionDx–Melanoma test outperforms current standards for identifying...